TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single-center, Randomized, Controlled Clinical Study of the Effects of Modified and Traditional BII+Braun Digestive Tract Reconstruction Methods on Quality of Life After Radical Gastrectomy for Distal Gastric Cancer
Brief Summary: The jejunum of the input segment is properly ligated with double line 7 at 3-5cm from the anastomotic site, and the jejunum of the output segment is extended to 30cm


Options:
A: Arm Label: modified BII+Braun; Type: ACTIVE_COMPARATOR; Interventions: Procedure: modified BII+Braun | Arm Label: traditional BII+Braun; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: modified BII+Braun; Assigned to Arm(s): modified BII+Braun
B: Arm Label: the group of Roux-en-Y; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Roux-en-Y reconstruction | Arm Label: the group of Uncut Roux-en-Y; Type: EXPERIMENTAL; Interventions: Procedure: Uncut Roux-en-Y reconstruction | Intervention Type: PROCEDURE; Name: Uncut Roux-en-Y reconstruction; Assigned to Arm(s): the group of Uncut Roux-en-Y | Intervention Type: PROCEDURE; Name: Roux-en-Y reconstruction; Assigned to Arm(s): the group of Roux-en-Y
C: Arm Label: Uncut Roux-en-Y Reconstruction; Type: EXPERIMENTAL; Interventions: Procedure: Uncut Roux-en-Y Reconstruction | Arm Label: Billroth II Reconstruction; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Billroth II Reconstruction | Intervention Type: PROCEDURE; Name: Uncut Roux-en-Y Reconstruction; Assigned to Arm(s): Uncut Roux-en-Y Reconstruction | Intervention Type: PROCEDURE; Name: Billroth II Reconstruction; Assigned to Arm(s): Billroth II Reconstruction
D: Arm Label: Roux-en Y; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Roux-en Y reconstruction | Arm Label: Billroth-I; Type: EXPERIMENTAL; Interventions: Procedure: Billroth-I reconstruction | Intervention Type: PROCEDURE; Name: Roux-en Y reconstruction; Assigned to Arm(s): Roux-en Y | Intervention Type: PROCEDURE; Name: Billroth-I reconstruction; Assigned to Arm(s): Billroth-I

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter Randomized Trial of Personalized Acupuncture, Fixed Acupuncture, Letrozole and Placebo on Live Birth for Infertility in Women With Polycystic Ovary Syndrome
Brief Summary: This study is a randomized assessor-blind controlled trial. A total of 1,100 women with PCOS will be recruited from 28 hospitals and randomly allocated into four groups: personalized acupuncture, fixed acupuncture, letrozole or placebo letrozole. Patients will receive treatment for 16 weeks and the primary outcome is live birth.


Options:
A: Arm Label: Personalized acupuncture; Type: EXPERIMENTAL; Interventions: Other: Acupuncture | Arm Label: Fixed acupuncture; Type: EXPERIMENTAL; Interventions: Other: Acupuncture | Arm Label: Letrozole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Letrozole | Arm Label: Placebo letrozole; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo letrozole | Intervention Type: OTHER; Name: Acupuncture; Assigned to Arm(s): Fixed acupuncture, Personalized acupuncture | Intervention Type: DRUG; Name: Letrozole; Assigned to Arm(s): Letrozole | Intervention Type: DRUG; Name: Placebo letrozole; Assigned to Arm(s): Placebo letrozole
B: Arm Label: Clomiphene citrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomifene citrate | Arm Label: Letrozole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Letrozole | Intervention Type: DRUG; Name: Letrozole; Assigned to Arm(s): Letrozole | Intervention Type: DRUG; Name: Clomifene citrate; Assigned to Arm(s): Clomiphene citrate
C: Arm Label: letrozole group; Type: EXPERIMENTAL; Interventions: Drug: letrozole | Arm Label: natural cycle group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: letrozole; Assigned to Arm(s): letrozole group
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clomiphene citrate | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Letrozole | Intervention Type: DRUG; Name: Clomiphene citrate; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Letrozole; Assigned to Arm(s): B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Haloperidol to Decrease the Burden of Delirium in Adult Critically Ill Patients (EuRIDICE): a Prospective Randomised Multi-center Double-blind Placebo-controlled Clinical Trial
Brief Summary: The EuRIDICE trial will study whether haloperidol as a first line treatment for ICU delirium reduces delirium duration (and severity). Adverse outcomes typically associated with delirium will also be studied and include long term cognition, functional outcome and quality of life. Further, patient and family experiences and cost-effectiveness will be assessed. Finally, safety concerns associated with the use of haloperidol in this vulnerable population will be studied.


Options:
A: Arm Label: haloperidol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Haloperidol | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Haloperidol; Assigned to Arm(s): haloperidol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: N/A
C: Arm Label: Dexmedetomidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Saline placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline placebo | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Saline placebo; Assigned to Arm(s): Saline placebo
D: Arm Label: Dexmedetomidine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Lorazepam group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorazepam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine group | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Lorazepam group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Canine Assisted Therapy to Reduce Emergency Care Provider Stress
Brief Summary: The main study hypothesis is that emergency healthcare workers on shift who interact for 5 min with a therapy dog and handler will have lower perceived and manifested stress response compared with use of a time out that includes voluntary use of a coloring mandalas. The work will also address two exploratory hypotheses: The first is that salivary cortisol will correlate significantly with perceived stress and will increase from beginning to end of shift, and that exposure to a therapy dog will blunt this increase. The second exploratory hypothesis states that participants who interact with a therapy dog will display more empathic behaviors.


Options:
A: Arm Label: A treatment based on CBT and new technologies; Type: EXPERIMENTAL; Interventions: Behavioral: Coping skills and relaxation training with new technologies | Arm Label: Traditional treatment based on CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Traditional coping skills and relaxation training | Intervention Type: BEHAVIORAL; Name: Coping skills and relaxation training with new technologies; Assigned to Arm(s): A treatment based on CBT and new technologies | Intervention Type: BEHAVIORAL; Name: Traditional coping skills and relaxation training; Assigned to Arm(s): Traditional treatment based on CBT
B: Arm Label: Sudarshan Kroya Yoga (SKY); Type: EXPERIMENTAL; Interventions: Other: Sudarshan Kriya Yoga (SKY) | Arm Label: Health Enhancement Program (HEP); Type: ACTIVE_COMPARATOR; Interventions: Other: Health Enhancement Program | Intervention Type: OTHER; Name: Sudarshan Kriya Yoga (SKY); Assigned to Arm(s): Sudarshan Kroya Yoga (SKY) | Intervention Type: OTHER; Name: Health Enhancement Program; Assigned to Arm(s): Health Enhancement Program (HEP)
C: Arm Label: ACTIVE; Type: EXPERIMENTAL; Interventions: Behavioral: Mayo Clinic SMART program (Stress Management and Resilience Training) | Arm Label: CONTROL; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mayo Clinic SMART program (Stress Management and Resilience Training); Assigned to Arm(s): ACTIVE
D: Arm Label: Therapy Dog; Type: EXPERIMENTAL; Interventions: Behavioral: Dog Therapy | Arm Label: Mandala Coloring; Type: EXPERIMENTAL; Interventions: Behavioral: Coloring | Arm Label: No Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dog Therapy; Assigned to Arm(s): Therapy Dog | Intervention Type: BEHAVIORAL; Name: Coloring; Assigned to Arm(s): Mandala Coloring

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of a Training Program in Mindfulness and Self-Compassion of 4 Sessions in Front of the 8 Sessions to Reduce Work Stress and Burnout in Professionals of Medicine and Nursing (MINDUUDD Project)
Brief Summary: The objective is to check whether a training program in mindfulness and self-pity based on a 4-session intervention (abbreviated program) is as effective as the standard 8-session MBSR program in reducing work stress and burnout in tutors and residents of Medicine and Family and Community Nursing.

It is a controlled clinical trial, randomized by cluster, of three parallel arms, multicentric. Six teaching units (ratio 1: 1: 1) will be randomized to one of the three study groups: 1) Experimental Group-8 (EG8); 2) Experimental Group-4 (EG4); 3) Control group (CG).

At least 132 subjects will participate, 44 in the EG8, 44 in the EG4 and 44 in the CG.

The interventions will be based on the MBSR (Mindfulness Based Stress Reduction) program, to which some of the practices of the MSC (Mindful Self-Compassion) program will be added.

The EG8 intervention will be carried out during 8 weekly sessions of 2.5 hours, while the EG4 intervention will be of 4 sessions of 2.5 hours. The participants will have to practice at home for 30 minutes / day in the EG8 and 15 minutes / day in the EG4.

In the 3 groups the questionnaires FFMQ (mindfulness), SCS (self-pity), ordinal scale (0-10) and questionnaire PSQ (perceived stress) and MBI (burnout) will be passed. Empathy will also be measured, through the EEMJ, anxiety and depression disorders (EADG) and self-perceived health status.


Options:
A: Arm Label: Induction; Type: EXPERIMENTAL; Interventions: Other: Induction | Arm Label: Control group; Type: OTHER; Interventions: Other: Control group | Intervention Type: OTHER; Name: Induction; Assigned to Arm(s): Induction | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group
B: Arm Label: Intervention group 4s (mindfulness); Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness and Mindful Self-Compassion | Arm Label: Intervention group 8s (mindfulness); Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness and Mindful Self-Compassion | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness and Mindful Self-Compassion; Assigned to Arm(s): Intervention group 4s (mindfulness), Intervention group 8s (mindfulness)
C: Arm Label: Control App; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Flourishing App Program; Type: EXPERIMENTAL; Interventions: Behavioral: Flourishing App Program | Intervention Type: BEHAVIORAL; Name: Flourishing App Program; Assigned to Arm(s): Flourishing App Program
D: Arm Label: Mindful Awareness Practices (MAPs); Type: EXPERIMENTAL; Interventions: Behavioral: Mindful Awareness Practices (MAPs) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindful Awareness Practices (MAPs); Assigned to Arm(s): Mindful Awareness Practices (MAPs)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase Ib Study of Tisagenlecleucel in Combination With Pembrolizumab in Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) Patients.
Brief Summary: A multi-center, open-label, phase Ib study to evaluate the safety and efficacy of the administration of tisagenlecleucel in combination with pembrolizumab in patients with r/r DLBCL who have received 2 or more lines of systemic therapy, including an anti-CD20 and anthracycline based chemotherapy and having failed to or are not candidates for ASCT. The study will consist of 2 parts: dose timing selection part and expansion part.


Options:
A: Arm Label: CD19-CART01; Type: EXPERIMENTAL; Interventions: Biological: CD19-CAR T cell | Intervention Type: BIOLOGICAL; Name: CD19-CAR T cell; Assigned to Arm(s): CD19-CART01
B: Arm Label: Administration of JCAR017; Type: EXPERIMENTAL; Interventions: Drug: JCAR017 | Intervention Type: DRUG; Name: JCAR017; Assigned to Arm(s): Administration of JCAR017
C: Arm Label: Tisagenlecleucel+Pembrolizumab; Type: EXPERIMENTAL; Interventions: Biological: Tisagenlecleucel, Drug: Pembrolizumab | Intervention Type: BIOLOGICAL; Name: Tisagenlecleucel; Assigned to Arm(s): Tisagenlecleucel+Pembrolizumab | Intervention Type: DRUG; Name: Pembrolizumab; Assigned to Arm(s): Tisagenlecleucel+Pembrolizumab
D: Arm Label: Single dose of CTL019; Type: EXPERIMENTAL; Interventions: Biological: CTL019 | Intervention Type: BIOLOGICAL; Name: CTL019; Assigned to Arm(s): Single dose of CTL019

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effectiveness of a Low-intensity, Lay Counsellor-delivered, Problem-solving Intervention for Common Mental Health Problems in School-going Adolescents in New Delhi, India: the PRIDE Study Protocol for a Randomized Controlled Trial
Brief Summary: We will conduct a two-arm individually randomized controlled trial in six Government-run secondary schools in New Delhi. The targeted sample is 240 adolescents in grades 9-12 with persistent, elevated mental health difficulties and associated impact. Participants will receive either a brief problem-solving intervention delivered by lay counsellors (intervention), or enhanced usual care comprised of problem-solving booklets (control). Self-reported adolescent mental health difficulties and idiographic problems will be assessed at 6 weeks (co-primary outcomes) and again at 12 weeks post-randomization. In addition, adolescent-reported impact of mental health difficulties, perceived stress, mental wellbeing and clinical remission, as well as parent-reported adolescent mental health difficulties and impact scores, will be assessed at 6 and 12 weeks post-randomization. Parallel process evaluation, including estimations of the costs of delivering the interventions, will be conducted.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced usual care | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: PRIDE 'Step 1' problem-solving intervention | Intervention Type: BEHAVIORAL; Name: PRIDE 'Step 1' problem-solving intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Enhanced usual care; Assigned to Arm(s): Control
B: Arm Label: Specialist; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychotherapy | Arm Label: Enhanced Usual Care; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): Enhanced Usual Care, Specialist
C: Arm Label: Cognitive Processing Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Processing Therapy | Arm Label: Behavioral Activation; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation | Arm Label: non-specific counseling; Type: EXPERIMENTAL; Interventions: Behavioral: nonspecific counseling | Arm Label: wait control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy; Assigned to Arm(s): Cognitive Processing Therapy | Intervention Type: BEHAVIORAL; Name: Behavioral Activation; Assigned to Arm(s): Behavioral Activation | Intervention Type: BEHAVIORAL; Name: nonspecific counseling; Assigned to Arm(s): non-specific counseling
D: Arm Label: Depression Care; Type: EXPERIMENTAL; Interventions: Combination Product: evidence-based depression treatment | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: COMBINATION_PRODUCT; Name: evidence-based depression treatment; Assigned to Arm(s): Depression Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX-659/TEZ/IVA Triple Combination Therapy in Cystic Fibrosis Subjects 6 Through 11 Years of Age
Brief Summary: This study will evaluate the pharmacokinetics (PK), safety, tolerability, efficacy, and pharmacodynamic effect of VX-659, tezacaftor (TEZ), and ivacaftor (IVA) when dosed in triple combination (TC) in Cystic Fibrosis (CF) subjects with F/F or F/MF genotypes.

The study was discontinued after completion of Part A due to Sponsor's discretion.


Options:
A: Arm Label: VX-659/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: VX-659/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: VX-659/TEZ/IVA; Assigned to Arm(s): VX-659/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): VX-659/TEZ/IVA
B: Arm Label: Part A; Type: EXPERIMENTAL; Interventions: Drug: lumacaftor, Drug: ivacaftor | Arm Label: Part B; Type: EXPERIMENTAL; Interventions: Drug: lumacaftor, Drug: ivacaftor | Intervention Type: DRUG; Name: lumacaftor; Assigned to Arm(s): Part A, Part B | Intervention Type: DRUG; Name: ivacaftor; Assigned to Arm(s): Part A, Part B
C: Arm Label: VX-659/TEZ/IVA TC; Type: EXPERIMENTAL; Interventions: Drug: VX-659/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: VX-659/TEZ/IVA; Assigned to Arm(s): VX-659/TEZ/IVA TC | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): VX-659/TEZ/IVA TC
D: Arm Label: Arm 1 Part A: LUM 600 mg qd/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: Arm 2 Part A: Placebo - LUM 600 mg qd/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: Arm 3 Part A: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Arm Label: Arm 4 Part A: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Arm Label: Arm 5 Part A: Observational Cohort; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm 6 Part B: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Arm Label: Arm 7 Part B: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Intervention Type: DRUG; Name: Lumacaftor Plus Ivacaftor Combination; Assigned to Arm(s): Arm 1 Part A: LUM 600 mg qd/ IVA 250 mg q12h, Arm 2 Part A: Placebo - LUM 600 mg qd/ IVA 250 mg q12h, Arm 3 Part A: LUM 400 mg q12h/ IVA 250 mg q12h, Arm 4 Part A: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h, Arm 6 Part B: LUM 400 mg q12h/ IVA 250 mg q12h, Arm 7 Part B: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Arm 1 Part A: LUM 600 mg qd/ IVA 250 mg q12h, Arm 2 Part A: Placebo - LUM 600 mg qd/ IVA 250 mg q12h

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX-659/TEZ/IVA Triple Combination Therapy in Cystic Fibrosis Subjects 6 Through 11 Years of Age
Brief Summary: This study will evaluate the pharmacokinetics (PK), safety, tolerability, efficacy, and pharmacodynamic effect of VX-659, tezacaftor (TEZ), and ivacaftor (IVA) when dosed in triple combination (TC) in Cystic Fibrosis (CF) subjects with F/F or F/MF genotypes.

The study was discontinued after completion of Part A due to Sponsor's discretion.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: VX-809, 25 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 50 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 100 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Arm Label: VX-809, 200 mg; Type: EXPERIMENTAL; Interventions: Drug: VX-809 | Intervention Type: DRUG; Name: VX-809; Assigned to Arm(s): VX-809, 100 mg, VX-809, 200 mg, VX-809, 25 mg, VX-809, 50 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Part A: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Arm Label: Part B: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: ELX/TEZ/IVA; Assigned to Arm(s): Part A: ELX/TEZ/IVA, Part B: ELX/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): Part A: ELX/TEZ/IVA, Part B: ELX/TEZ/IVA
C: Arm Label: Part A: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM, Drug: IVA | Arm Label: Part B: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM, Drug: IVA | Intervention Type: DRUG; Name: LUM; Assigned to Arm(s): Part A: LUM/IVA, Part B: LUM/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): Part A: LUM/IVA, Part B: LUM/IVA
D: Arm Label: VX-659/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: VX-659/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: VX-659/TEZ/IVA; Assigned to Arm(s): VX-659/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): VX-659/TEZ/IVA

Answer: D